182 related articles for article (PubMed ID: 28122579)
1. The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario.
Franklyn AM; Eibl JK; Gauthier G; Pellegrini D; Lightfoot NE; Marsh DC
Harm Reduct J; 2017 Jan; 14(1):6. PubMed ID: 28122579
[TBL] [Abstract][Full Text] [Related]
2. The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada.
Franklyn AM; Eibl JK; Gauthier GJ; Pellegrini D; Lightfoot NE; Marsh DC
Int J Drug Policy; 2017 Oct; 48():1-8. PubMed ID: 28666202
[TBL] [Abstract][Full Text] [Related]
3. The impact of benzodiazepine use on methadone maintenance treatment outcomes.
Brands B; Blake J; Marsh DC; Sproule B; Jeyapalan R; Li S
J Addict Dis; 2008; 27(3):37-48. PubMed ID: 18956528
[TBL] [Abstract][Full Text] [Related]
4. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Morford KL; Tetrault JM; Zhou B; Li F; Gleeson B; Edelman EJ; Stein MD; Barry DT; Madden L
Drug Alcohol Depend; 2022 Dec; 241():109707. PubMed ID: 36423462
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Impact of Prescribed Versus Nonprescribed Benzodiazepine Use in Methadone Maintenance Therapy: Results From a Population-based Retrospective Cohort Study.
Eibl JK; Wilton AS; Franklyn AM; Kurdyak P; Marsh DC
J Addict Med; 2019; 13(3):182-187. PubMed ID: 30543543
[TBL] [Abstract][Full Text] [Related]
6. The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada.
Franklyn AM; Eibl JK; Gauthier GJ; Marsh DC
PLoS One; 2017; 12(11):e0187633. PubMed ID: 29117267
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada.
Eibl JK; Gomes T; Martins D; Camacho X; Juurlink DN; Mamdani MM; Dhalla IA; Marsh DC
J Addict Med; 2015; 9(6):440-6. PubMed ID: 26484843
[TBL] [Abstract][Full Text] [Related]
8. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention.
White WL; Campbell MD; Spencer RD; Hoffman HA; Crissman B; DuPont RL
J Psychoactive Drugs; 2014; 46(2):114-22. PubMed ID: 25052787
[TBL] [Abstract][Full Text] [Related]
9. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial.
Eiroa-Orosa FJ; Haasen C; Verthein U; Dilg C; Schäfer I; Reimer J
Drug Alcohol Depend; 2010 Dec; 112(3):226-33. PubMed ID: 20708349
[TBL] [Abstract][Full Text] [Related]
10. Gender-specific predictors of retention and opioid abstinence during methadone maintenance treatment.
Levine AR; Lundahl LH; Ledgerwood DM; Lisieski M; Rhodes GL; Greenwald MK
J Subst Abuse Treat; 2015 Jul; 54():37-43. PubMed ID: 25795601
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of QTc changes among former opiate addicts since admission to methadone maintenance treatment: benzodiazepine risk.
Peles E; Linzy S; Kreek MJ; Adelson M
J Addict Med; 2013; 7(6):428-34. PubMed ID: 24145160
[TBL] [Abstract][Full Text] [Related]
12. Retention in Georgia opioid substitution therapy program and associated factors.
Ruadze E; Todadze K
Harm Reduct J; 2016 Dec; 13(1):35. PubMed ID: 27931232
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
[TBL] [Abstract][Full Text] [Related]
14. Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework.
Tahsin F; Morin KA; Vojtesek F; Marsh DC
BMC Health Serv Res; 2022 Apr; 22(1):490. PubMed ID: 35413980
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal patterns of benzodiazepine consumption in a German cohort of methadone maintenance treatment patients.
Specka M; Bonnet U; Heilmann M; Schifano F; Scherbaum N
Hum Psychopharmacol; 2011 Aug; 26(6):404-11. PubMed ID: 21823170
[TBL] [Abstract][Full Text] [Related]
16. J-shaped relationship between supervised methadone consumption and retention in methadone maintenance treatment (MMT) in primary care: National cohort study.
Cousins G; Boland F; Barry J; Lyons S; Keenan E; O'Driscoll D; Bennett K; Fahey T
Drug Alcohol Depend; 2017 Apr; 173():126-131. PubMed ID: 28232249
[TBL] [Abstract][Full Text] [Related]
17. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
Nielsen S; Dietze P; Lee N; Dunlop A; Taylor D
Addiction; 2007 Apr; 102(4):616-22. PubMed ID: 17286641
[TBL] [Abstract][Full Text] [Related]
18. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.
Sun EC; Dixit A; Humphreys K; Darnall BD; Baker LC; Mackey S
BMJ; 2017 Mar; 356():j760. PubMed ID: 28292769
[No Abstract] [Full Text] [Related]
19. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
Sankey C; Setnik B; Harsanyi Z; Michalko K; Yang Z; Geoffroy P
J Opioid Manag; 2016; 12(2):149-59. PubMed ID: 27194200
[TBL] [Abstract][Full Text] [Related]
20. Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Peles E; Schreiber S; Rados V; Adelson M
J Addict Med; 2011 Sep; 5(3):214-20. PubMed ID: 21844836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
